Skip to main content

Table 2 Characteristics of antiretroviral treatment-experienced HIV/HBV Co-infected patients with undetectable HBVDNA compared to those with detectable HBV DNA

From: Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients

Characteristic HBV DNA < 20 HBV DNA ≥ 20 P-value T test P-value Wilcoxon rank sum test
IU/mL (N = 64) IU/mL (N = 88)
Mean (SD) age (years) 42.6 (9.6) 42.7 (9.5) 0.928 0.701
Mean (SD) weight (kg) 65.9 (13.7) 63.5 (12.2) 0.262 0.326
Mean (SD) BMI (kg/m2) 24.5 (4.6) 23.9 (4.7) 0.415 0.432
Mean (SD) CD4 count (cells/uL) 539 (257) 478 (358) 0.244 0.157
  n (%) n (%) P value Chi square P value Fisher
Male sex 30 (46.9 %) 34 (53.1 %) 0.019 0.021
Ethnicity    0.656 0.679
 Akan 43 (59.7 %) 29 (40.3 %)   
 Ewe 14 (48.3 %) 15 (51.7 %)   
 Ga 13 (65.0 %) 7 (35.0 %)   
 Other 18 (58.1 %) 13 (41.9 %)   
WHO HIV stage    0.086 0.095
 1 24 (63.2 %) 14 (36.8 %)   
 2 21 (58.3 %) 15 (41.7 %)   
 3 37 (60.7 %) 24 (39.3 %)   
 4 4 (26.7 %) 11 (73.3 %)   
HBeAg positive 0 28 (100.0 %) <0.0001 <0.0001
HBeAb positive 85 (69.7 %) 37 (30.3 %) <0.0001 <0.0001
HB eAg/E Ab combination    <0.0001 <0.0001
HBeAg positive/Ab negative 0 25 (100.0 %)   
HBeAg negative/Ab positive 85 (71.4 %) 34 (28.6 %)   
HBeAg negative/Ab negative 3 (60.0 %) 2 (40.0 %)   
HBeAg positive/Ab positive 0 3 (100.0 %)   
HBcIgM positive 0 4 (100.0 %) 0.0175 0.030
Alanine aminotransferase    0.0001 0.0002
 Normal (5-40 U/L) 79 (65.8 %) 41 (34.2 %)   
 Elevated > ULN 9 (28.1 %) 23 (71.9 %)   
Aspartate aminotransferase    0.0004 0.0008
 Normal (5-50 U/L) 81 (64.3 %) 45 (35.7 %)   
Elevated > ULN 7 (26.9 %) 19 (73.1 %)   
Characteristic HBV DNA < 20 IU mL-1 HBV DNA ≥ 20 IU mL-1 P value Chi square P value Fisher
n (%) n (%)
Albumin    0.096 0.119
 Normal (36-50 g/L) 72 (61.5 %) 45 (38.5 %)   
 Low < LLN 16 (45.7 %) 19 (54.3 %)   
Initial ART contain    0.971 1.000
 3TC (n = 100) 42 (42.0 %) 58 (58.0 %)   
 3TC + TDF (n = 52) 22 (42.3 %) 30 (57.7 %)   
Duration on ART    0.969 0.972
<1 year 3 (75.0 %) 1 (25.0 %)   
 1 – 2 years 22 (57.9 %) 16 (42.1 %)   
 2 – 3 years 12 (57.1 %) 9 (42.9 %)   
  > 3 years 51 (57.3 %) 38 (42.7 %)   
Ever forgotten meds? 26 (72.2 %) 10 (27.8 %) 0.046  
Do you take meds on time? 8 (50.0 %) 8 (50.0 %) 0.499  
Stop taking meds due to illness? 9 (75.0 %) 3 (25.0 %) 0.211  
Forgotten meds last weekend? 10 (71.4 %) 4 (28.6 %) 0.282  
Number of times not taken meds last week?    --  
 0 35 (61.4 %) 22 (38.6 %)   
 1 - 2 7 (70.0 %) 3 (30.0 %)   
 3 – 5 4 (66.7 %) 2 (33.3 %)   
 more than 5 1 (33.3 %) 2 (66.7 %)   
  1. BMI body mass index
  2. HBeAg/Ab Hepatitis B e Antigen/Antibody
  3. HBcIgM Hepatitis B core IgM
  4. 3TC lamivudine
  5. TDF tenofovir
  6. ULN upper limit of normal
  7. LLN lower limit of normal
  8. ART anti-retroviral therapy